Table 1 Characteristics, In-ICU organ failures and outcomes of the study population
Variables | n = 47 |
|---|---|
Female | 25 (53) |
Body mass index, kg/m2 | 23.9 [21.4–27.8] |
Age at admission, years | 41 [30–47] |
Past medical history | |
Cardiovascular comorbidities | 9 (19) |
Autoimmune/autoinflammatory disease | 8 (17) |
Allergic disease | 7 (15) |
Cancer | 4 (8) |
Myocarditis | 2 (4) |
Day-0 ICU scores | |
Charlson comorbidity index | 0 [0–1] |
Day-0 SAPS II score | 45 [33–65] |
Day-0 SOFA score | 10 [6–15] |
In-ICU organ failures | |
Circulatory failure | |
Highest arterial lactate value, mmol/L | 7 [4–13] |
Inotropes/vasopressors | 46 (98) |
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) | 42 (89) |
Femoro-femoral cannulation | 39/42 (93) |
Secondary centralization | 26/42 (62) |
Time on VA-ECMO, days | 16 [9–34] |
Left ventricular venting under VA-ECMO | 25 (53) |
Intra-aortic balloon counterpulsation | 23 (49) |
IMPELLA® device | 4 (8) |
Ventricular assist device (VAD) | 15 (32) |
Left ventricular assist device | 8/15 (53) |
Bi-ventricular assist device | 7/15 (47) |
Time on VAD, days | 23 [17–219] |
Respiratory failure | |
Mechanical ventilation | 44 (94) |
Time on mechanical ventilation, days | 21 [10–36] |
Renal failure | |
Renal replacement therapy (RRT) | 24 (51) |
Time on RRT, days | 14 [2–18] |
Highest in-ICU serum creatinine value, µmol/L | 161 [102–268] |
Hematological failure | |
Lowest in-ICU platelet count, G/L | 41 [24–71] |
Liver failure | |
Highest in-ICU ALT value, UI/L | 574 [288–1736] |
Highest in-ICU bilirubin value, µmol/L | 61 [28–134] |
Lowest in-ICU prothrombin time, % | 39 [27–47] |
Outcomes | |
Duration of follow-up, months | 3 [1–87] |
Time in ICU, days | 22 [15–41] |
Time in hospital, days | 38 [22–74] |
Bridge-to-recovery | 16 (34) |
LVEF recovery > 50% | 12 (25) |
Bridge-to-transplant | 7 (15) |
In-hospital mortality | 26 (55) |